851 related articles for article (PubMed ID: 26659826)
1. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
Terrill JR; Boyatzis A; Grounds MD; Arthur PG
Int J Biochem Cell Biol; 2013 Sep; 45(9):2097-108. PubMed ID: 23892094
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
4. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.
Terrill JR; Duong MN; Turner R; Le Guiner C; Boyatzis A; Kettle AJ; Grounds MD; Arthur PG
Redox Biol; 2016 Oct; 9():276-286. PubMed ID: 27611888
[TBL] [Abstract][Full Text] [Related]
5. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
Terrill JR; Grounds MD; Arthur PG
Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
Barker RG; Wyckelsma VL; Xu H; Murphy RM
Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
[TBL] [Abstract][Full Text] [Related]
7. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
8. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
[TBL] [Abstract][Full Text] [Related]
9. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
[TBL] [Abstract][Full Text] [Related]
11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effect of taurine supplementation on muscle taurine content in the mdx mouse model of Duchenne muscular dystrophy using chemically specific synchrotron imaging.
Terrill JR; Webb SM; Arthur PG; Hackett MJ
Analyst; 2020 Nov; 145(22):7242-7251. PubMed ID: 32893271
[TBL] [Abstract][Full Text] [Related]
15. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
[TBL] [Abstract][Full Text] [Related]
16. Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation.
Terrill JR; Grounds MD; Arthur PG
PLoS Curr; 2016 Apr; 8():. PubMed ID: 27679740
[TBL] [Abstract][Full Text] [Related]
17. Hypochlorous acid exposure impairs skeletal muscle function and Ca
Lea TA; Panizza PM; Arthur PG; Bakker AJ; Pinniger GJ
J Physiol; 2023 Dec; 601(23):5257-5275. PubMed ID: 37864413
[TBL] [Abstract][Full Text] [Related]
18. The location of protein oxidation in dystrophic skeletal muscle from the mdx mouse model of Duchenne muscular dystrophy.
Iwasaki T; Terrill JR; Kawarai K; Miyata Y; Tagami T; Maeda N; Hasegawa Y; Watanabe T; Grounds MD; Arthur PG
Acta Histochem; 2022 Dec; 124(8):151959. PubMed ID: 36270048
[TBL] [Abstract][Full Text] [Related]
19. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
[TBL] [Abstract][Full Text] [Related]
20. Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the
Terrill JR; Huchet C; Le Guiner C; Lafoux A; Caudal D; Tulangekar A; Bryson-Richardson RJ; Sztal TE; Grounds MD; Arthur PG
Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
